CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma

Blood

Volumn 102, Issue 3, 2003, Pages 1070-1071

  Robillard, Nelly ^b   Avet Loiseau, Hervó ^b   Garand, Richard ^b   Moreau, Philippe ^b   Pineau, Danielle ^b   Rapp, Marie Josée ^b   Harousseau, Jean Luc ^b   Bataille, Régis ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL STRUCTURE; CHROMOSOME TRANSLOCATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

EID: 0042744766     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3333     Document Type: Article

References (17)

1. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood. 2002; 99:2185-2191.
2. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-1583.
3. Jackson N, Ling NR, Ball J, Bromidge E, Nathan PD, Franklin IM. An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd international workshop on human leucocyte differentiation antigens. Clin Exp Immunol. 1988; 72:351-356.
4. San Miguel F, Gonzalez M, Gascon A, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of disease. Br J Haematol. 1991;77:185-190.
5. + is the common phenotype of myeloma cells. Ann Hematol. 1992;64: 132-139.
6. Harada H, Kawano MM, Huang N, et al. A Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658-2663.
7. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Am J Pathol. 1998;152:1655-1665.
8. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.
9. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: significance of plasma-blastic subtype in morphological classification. Blood. 1985;65:305-310.
10. Goasguen JE, Zandecki M, Mathiot C, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leukemia Res. 1999;23:1133-1140.
11. Robillard N, Jego G, Pellat-Deceunynck C, et al. CD 28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res. 1998; 4:1521-1526.
12. Pellat-Deceunynck C, Barillé S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977-1982.
13. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87:341-355.
14. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurlin PJ. The (11;14) (q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol. 2000;113:831-837.
15. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14) (q13;q32): evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-3741.
16. Riley JK, Sliwkowski MX. CD 20: A gene in search of a function. Semin Oncol. 2000;27:17-24.
17. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25:72-81.